TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 773180

Group type: EXPERIMENTAL
Intervention: Carbenicillin
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Carbenicillin plus gentamicin
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cephalothin plus gentamicin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Single antibiotic therapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 49
Study: 31786218

Group type: EXPERIMENTAL
Intervention: Nitinol stents
Number of subjects: 110

Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 110
Study: 28791690

Group type: EXPERIMENTAL
Intervention: Apathy present (measured using the Apathy Evaluation Scale - AES-10)
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Apathy present (controlled for depressive symptoms)
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Apathy as a dimensional construct (1 standard deviation increase in AES-10 scores)
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Higher age in years
Number of subjects: 713
Study: 25580665

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin detemir
Number of subjects: 11

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 11
Study: 23317685

Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone film
Number of subjects: 92

Group type: COMPARATOR
Intervention: Buprenorphine-naloxone tablets
Number of subjects: 92
Study: 21275531

Group type: EXPERIMENTAL
Intervention: Low-level, dual-wavelength laser and massage device
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control (untreated contralateral thigh)
Number of subjects: 83
Study: 19006538

Group type: EXPERIMENTAL
Intervention: Nadolol + prazosin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nadolol + ligation
Number of subjects: 59
Study: 16951997

Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg/kg intravenously over 2.5 min)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Tramadol (additional 0.33 mg/kg if pain relief was inadequate)
Number of subjects: 104
Study: 15532659

Group type: EXPERIMENTAL
Intervention: Masker cue preceding a yes/no trial interval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random frequency signal detection
Number of subjects: 0
Study: 11502949

Group type: EXPERIMENTAL
Intervention: Enhanced care (intervention) for uninsured patients
Number of subjects: 383

Group type: COMPARATOR
Intervention: Usual care for uninsured patients (control)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Usual care for insured patients (control)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Enhanced care for insured patients
Number of subjects: 383
Study: 9236672

Group type: EXPERIMENTAL
Intervention: Serum pentosidine levels in RA patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Urinary pentosidine levels in RA patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Pentosidine levels in active RA patients
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Correlation of pentosidine with clinical features
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Serum and urinary pentosidine levels
Number of subjects: 77
Study: 10137016

Group type: EXPERIMENTAL
Intervention: Likert‐type scale form (1 = Strongly Agree, 5 = Strongly Disagree)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Mixed scale form (1 = Very Satisfied, 5 = Very Dissatisfied)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Expectational scale form (1 = More Than I Expected, 5 = Less Than I Expected)
Number of subjects: 159
Study: 3299618

Group type: EXPERIMENTAL
Intervention: Antilymphocyte serum, azathioprine, and prednisone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Azathioprine and prednisone only (Control)
Number of subjects: 45
Study: 29488274

Group type: EXPERIMENTAL
Intervention: Authentic electroacupuncture
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 200
Study: 28111123

Group type: EXPERIMENTAL
Intervention: Broaching
Number of subjects: 42

Group type: COMPARATOR
Intervention: Compaction
Number of subjects: 42
Study: 24671434

Group type: EXPERIMENTAL
Intervention: Dance intervention (10 dance classes in 5 weeks in addition to counselling)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no dance, standard of care, counselling)
Number of subjects: 40
Study: 23530946

Group type: EXPERIMENTAL
Intervention: Dorzolamide 2%-timolol 0.5% (D/T)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%-timolol 0.5% (B/T)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 21
Study: 20558416

Group type: EXPERIMENTAL
Intervention: Indometacin (100-200 mg intramuscularly or orally)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Indometacin (oral or intramuscular)
Number of subjects: 39
Study: 18216286

Group type: EXPERIMENTAL
Intervention: CGRP(8‐37) (1200 ng . min(‐1) . dl(‐1) forearm)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Indomethacin (5 mug . min(‐1) . dl(‐1) forearm)
Number of subjects: 22

Group type: COMPARATOR
Intervention: l‐NMMA (0.2 mg . min(‐1) dl(‐1) forearm)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Aprepitant (375 mg orally)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Time of assessment
Number of subjects: 22
Study: 16310920

Group type: EXPERIMENTAL
Intervention: 5% NaOCl for 120 s
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10% NaOCl for 30 s
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10% NaOCl for 60 s
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10% NaOCl for 120 s
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (without AE and NaOCl)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Only AE
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5% NaOCl for 30 s
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5% NaOCl for 60 s
Number of subjects: 40
Study: 12690270

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 455

Group type: COMPARATOR
Intervention: Cefadroxil
Number of subjects: 455
Study: 11060831

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 4024
Study: 8624086

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory drugs
Number of subjects: 0
Study: 8157776

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Coronally positioned flap (CPF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Radiographic assessment (GTR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Radiographic assessment (CPF)
Number of subjects: 8
Study: 3262320

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Thiopentone 5 mg/kg
Number of subjects: 120
Study: 31013466

Group type: EXPERIMENTAL
Intervention: T-CBT with letters
Number of subjects: 59

Group type: COMPARATOR
Intervention: T-CBT without letters
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Total sample (both groups)
Number of subjects: 59
Study: 29940209

Group type: EXPERIMENTAL
Intervention: PREPARE + AD
Number of subjects: 0

Group type: COMPARATOR
Intervention: AD-only
Number of subjects: 0
Study: 28914131

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA injections (maximum total dose per injection cycle: 30 U/kg or 1000U) into the gastrocnemius-soleus complex and other muscles as required.
Number of subjects: 207
Study: 26030111

Group type: EXPERIMENTAL
Intervention: Inhalation challenges with terpenes and terpenoids
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intradermal challenges with volatile organic compounds (VOCs) including terpenes and terpenoids
Number of subjects: 45

Group type: COMPARATOR
Intervention: Inhaled challenges
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intradermal challenges
Number of subjects: 45
Study: 23337413

Group type: EXPERIMENTAL
Intervention: Nitrous oxide anesthesia
Number of subjects: 5133
Study: 21388456

Group type: EXPERIMENTAL
Intervention: Oral retinoids (dosages between 10 and 25 mg, with stepwise escalation)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Retinoids as single agent therapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Retinoids combined with phototherapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Retinoids
Number of subjects: 44
Study: 17544212

Group type: EXPERIMENTAL
Intervention: 8-week mindfulness-based meditation program
Number of subjects: 37

Group type: COMPARATOR
Intervention: wait-list control group
Number of subjects: 37
Study: 16867088

Group type: EXPERIMENTAL
Intervention: Caudal block with bupivacaine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 52
Study: 14644692

Group type: EXPERIMENTAL
Intervention: Use of CONSORT guidelines in behavioral medicine research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral medicine-specific guidelines (e.g., treatment adherence)
Number of subjects: 0
Study: 10856098

Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) 50 mg/m² IV on day 1 and Vinorelbine (VNB) 25 mg/m² IV on days 1 and 8 (arm 1)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Doxorubicin (DOX) 70 mg/m² IV on day 1 (arm 2)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) 40 mg/m² IV on day 1 and Vinorelbine (VNB) 20 mg/m² IV on days 1 and 8 (arm 1) after dose reduction
Number of subjects: 300

Group type: COMPARATOR
Intervention: Doxorubicin (DOX) 60 mg/m² IV on day 1 (arm 2) after dose reduction
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 300
Study: 7474314

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg suppository just after induction of anesthesia (Group T)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg suppository about 90 min before incision (Group P)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 36
Study: 2318223

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 60 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6985835

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (C. parvum 4 mg subcutaneously weekly, along with chemotherapy)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Chemotherapy (vincristine, Daunorubicin, prednisone, Cytosine Arabinoside, and 6-mercaptopurine)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (13 mg/m2)
Number of subjects: 181
Study: 31659963

Group type: EXPERIMENTAL
Intervention: Two cannulated screws fixation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Three cannulated screws fixation
Number of subjects: 120
Study: 28759347

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT) after breast conservation surgery
Number of subjects: 1003
Study: 25265544

Group type: EXPERIMENTAL
Intervention: Integrative Behavioral Couple Therapy (IBCT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Traditional Behavioral Couple Therapy (TBCT)
Number of subjects: 134
Study: 24330473

Group type: EXPERIMENTAL
Intervention: Tactile Massage (TM)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Rest to Music (RTM)
Number of subjects: 45
Study: 21270442

Group type: EXPERIMENTAL
Intervention: Lestaurtinib (80 mg twice daily)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 224
Study: 19581801

Group type: EXPERIMENTAL
Intervention: Thromboelastometry (EXTEM and FIBTEM tests) in patients with overt DIC
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Thromboelastometry (EXTEM and FIBTEM tests) in patients without DIC
Number of subjects: 28

Group type: COMPARATOR
Intervention: Traditional coagulation assays
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curves for MCF, CFT, and alpha angle
Number of subjects: 28
Study: 17132720

Group type: EXPERIMENTAL
Intervention: I-CHOP
Number of subjects: 477

Group type: COMPARATOR
Intervention: Standard CHOP
Number of subjects: 477
Study: 15529604

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day + ranitidine 150 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day + 30 g alcohol/day
Number of subjects: 60
Study: 11369146

Group type: EXPERIMENTAL
Intervention: Pre-operative education
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no pre-operative education)
Number of subjects: 10
Study: 9664981

Group type: EXPERIMENTAL
Intervention: CSA-based immunosuppression
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: FK506-based immunosuppression
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Conversion from CsA to FK506
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Conversion from FK506 to CsA
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: OKT3 treatment
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 137
Study: 7622343

Group type: EXPERIMENTAL
Intervention: Inositol (12 gm daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Inositol
Number of subjects: 28
Study: 2513858

Group type: EXPERIMENTAL
Intervention: Extradural clonidine 150 micrograms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Morphine 4 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 1198939

Group type: EXPERIMENTAL
Intervention: Responses to simple step stimuli
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Responses to pulse step stimuli
Number of subjects: 10
Study: 30681726

Group type: EXPERIMENTAL
Intervention: Liver/Spleen Stiffness Measurement (LSSM) arm (n = 274)
Number of subjects: 548

Group type: COMPARATOR
Intervention: Conventional arm (n = 274)
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: LSSM arm
Number of subjects: 548

Group type: COMPARATOR
Intervention: Conventional arm
Number of subjects: 548
Study: 29949273

Group type: EXPERIMENTAL
Intervention: Warm normal saline distention solution (0.9% normal saline warmed up to 36⁰C)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Room temperature normal saline solution (0.9% normal saline at 25⁰C)
Number of subjects: 100
Study: 25934173

Group type: EXPERIMENTAL
Intervention: PARO therapy group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Psychosocial activities control group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 23287505

Group type: EXPERIMENTAL
Intervention: Subharmonic imaging (SHI)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Stopband (SB) filter
Number of subjects: 2

Group type: COMPARATOR
Intervention: Fundamental mode
Number of subjects: 2
Study: 21596257

Group type: EXPERIMENTAL
Intervention: Flap-off epi-LASIK with mitomycin-C (MMC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Flap-on epi-LASIK with mitomycin-C (MMC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Flap-on and flap-off epi-LASIK with mitomycin-C (MMC)
Number of subjects: 48
Study: 19307815

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16784467

Group type: EXPERIMENTAL
Intervention: Bridge protocol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bridge-less protocol
Number of subjects: 60
Study: 16281463

Group type: EXPERIMENTAL
Intervention: Data Monitoring Committees (DMCs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 100
Study: 10674280

Group type: EXPERIMENTAL
Intervention: Placebo substitution during interruption of paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 0
Study: 9342764

Group type: EXPERIMENTAL
Intervention: LI 160 (900 mg total daily dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline (75 mg total daily dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LI 160
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study: 8213020

Group type: EXPERIMENTAL
Intervention: Cervical epidural steroid/lidocaine injections (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Steroid/lidocaine injections into the posterior neck muscles (group B)
Number of subjects: 50
Study: 3924877

Group type: EXPERIMENTAL
Intervention: Mupirocin at 2 mg/l
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Mupirocin at various concentrations (0.015 to 0.06 mg/l)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Mupirocin at 2-4 mg/l
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Mupirocin at 16 mg/l
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Mupirocin at 32 mg/l
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Mupirocin at 1.0 mg/l or more for 120 h
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Mupirocin at 4 mg/l
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Mupirocin at 40 mg/l
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: 2% mupirocin topical treatment
Number of subjects: 750
Study: 31121030

Group type: EXPERIMENTAL
Intervention: Physical exercise intervention for 3 months
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study: 29678970

Group type: EXPERIMENTAL
Intervention: Remote care group (n=30) received care remotely for 6 months incorporating: home hearing in noise test, online support tool and self‐adjustment of device
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n=30) followed usual care pathway
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remote care group (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 60
Study: 26579847

Group type: EXPERIMENTAL
Intervention: C-MAC D-Blade
Number of subjects: 1100

Group type: COMPARATOR
Intervention: GlideScope
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 1100
Study: 23677131

Group type: EXPERIMENTAL
Intervention: 40 mg of simvastatin (n=40)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (n=39)
Number of subjects: 79
Study: 21715526

Group type: EXPERIMENTAL
Intervention: Full-nut dose (75 g/day mixed nuts)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Half-nut dose
Number of subjects: 117

Group type: COMPARATOR
Intervention: Muffin
Number of subjects: 117
Study: 19302259

Group type: EXPERIMENTAL
Intervention: Adenosine infusion (40 microg kg(‐1) min(‐1))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17507344

Group type: EXPERIMENTAL
Intervention: 4-kcal/kg per week exercise group
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: 8-kcal/kg per week exercise group
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: 12-kcal/kg per week exercise group
Number of subjects: 464

Group type: COMPARATOR
Intervention: Nonexercise control group
Number of subjects: 464
Study: 15509083

Group type: EXPERIMENTAL
Intervention: Regular brushing with dentifrices
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Use of toothbrushes and dentifrice
Number of subjects: 150
Study: 11548915

Group type: EXPERIMENTAL
Intervention: Torso immersion in cool water
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Hands and feet immersion in cool water
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Sit in shade with a 1.5mph breeze
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Mean heart rate readings
Number of subjects: 5
Study: 9271287

Group type: EXPERIMENTAL
Intervention: Self-paced brisk walking
Number of subjects: 165

Group type: COMPARATOR
Intervention: Upper limb exercises (placebo)
Number of subjects: 165
Study: 24234326

Group type: EXPERIMENTAL
Intervention: Work-oriented physical fitness course
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 148
Study: 3067745

Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 1% levobunolol
Number of subjects: 51

Group type: COMPARATOR
Intervention: 0.5% timolol
Number of subjects: 51
Study: 378735

Group type: EXPERIMENTAL
Intervention: Amoxycillin (1 g 8-hourly orally for fourteen days)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 62
Study: 31548149

Group type: EXPERIMENTAL
Intervention: Osteotome
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saw
Number of subjects: 10
Study: 30390234

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 60 mg once daily (QD) during open-label healing phase
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 30 mg QD during double-blind maintenance phase
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo during double-blind maintenance phase
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole 60 mg QD
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 28478635

Group type: EXPERIMENTAL
Intervention: DuraMax® (DM)
Number of subjects: 86

Group type: COMPARATOR
Intervention: SplitCath® (SC)
Number of subjects: 86
Study: 25622239

Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone Duphaston(®) (2× 10mg) administered two times daily
Number of subjects: 853

Group type: COMPARATOR
Intervention: Crinone 8%(®) vaginal progesterone gel (90mg) administered daily
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone Duphaston(®)
Number of subjects: 853

Group type: COMPARATOR
Intervention: Crinone 8%(®) vaginal progesterone gel
Number of subjects: 853
Study: 23876455

Group type: EXPERIMENTAL
Intervention: CBT+ART
Number of subjects: 77

Group type: COMPARATOR
Intervention: CBT+HLS
Number of subjects: 77
Study: 21337584

Group type: EXPERIMENTAL
Intervention: Preparation with fasting, water, laxatives, and antiflatulents (Group I)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Preparation with fasting, water, and antiflatulents alone (Group II)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Preparation with fasting and water alone (Group III)
Number of subjects: 611
Study: 20016175

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (no xylitol)
Number of subjects: 204
Study: 17550213

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Nontreated patients
Number of subjects: 37
Study: 15048662

Group type: EXPERIMENTAL
Intervention: Psychological treatments for weight loss
Number of subjects: 120

Group type: COMPARATOR
Intervention: C/C subjects in the obesity trial
Number of subjects: 120